Coherus sees up to $38M in Q1 Udenyca sales; shares up 5% after hours

|About: Coherus BioSciences, Inc. (CHRS)|By:, SA News Editor

On a preliminary basis, Coherus BioSciences (NASDAQ:CHRS) expects Q1 sales of Neulasta biosimilar UDENYCA (pegfilgrastim-cbqv) to be $36M - 38M, well above consensus of $2.8M.

The company will provide additional details during its Q1 conference call on May 9.

The European Commission approved the product in September 2018 followed by the FDA in November 2018.

Shares are up 5% after hours.

Subscribe for full text news in your inbox